Fuse Oncology Launches FuseRx Prescribing and Treatment Platform for Radiation Oncology

July 21, 2026
Fuse Oncology has launched FuseRx, a prescribing and treatment-intent platform for radiation oncology, debuting at the 2026 AAPM Annual Meeting in Vancouver. The system integrates prescribing, simulation, and treatment planning into one guided workflow with built-in validation and pathway support.

Fuse Oncology has launched FuseRx, a prescribing and treatment-intent solution for radiation oncology, announced in a press release. The system is being introduced at the 68th AAPM Annual Meeting and Exhibition in Vancouver.

FuseRx serves as a central component of the Fuse platform, linking consultation, simulation, planning, and treatment within a single structured workflow. It enables physicians to create a complete treatment plan, including simulation orders, prescriptions, and target goals, using configurable templates and a validation engine with safety checks and audit tracking.

The platform supports clinical pathways at the point of prescribing, incorporating both local protocols and published evidence-based guidelines. Integration with the American College of Radiation Oncology's ACROPath pathways provides clinicians with decision support during treatment planning, aimed at maintaining consistency while preserving physician discretion.

FuseRx operates alongside existing Fuse products, including S!GNAL and FuseDocs, within a unified system that shares patient data and workflow context from consultation onward. Attendees of AAPM 2026 can view the platform demonstration at booth #610.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

09/05
Tuya Smart Unveils Doova Home Robot for Seniors at IFA 2026
09/04
ODYSS Unveils N1 AI Necklace for Food Logging
09/04
Withings Adds AI Heart and Lung Sound Analysis to BeamO
09/03
CluePoints Releases Three AI Tools for Clinical Data Review
09/03
Authenticx Adds Form Automation and Routing to Safety AI

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like